Work

1114 Orally bioavailable small-molecule RXFP1 agonist TRND8394 potentiates immunotherapy in breast cancer models

Year: 2026
Type: conference-abstract
Abstract: Background Fibrotic remodeling of the tumor microenvironment contributes to tumor progression, therapeutic resistance, and immune exclusion in many solid tumors. Activation of Relaxin Family Peptide Receptor 1 (RXFP1) has been shown to reverse fibrosis in multiple organ systems; however, its therapeutic potential in cancer remains poorly defined. We evaluated whether pharmacological activation of human RXFP1 using TRND8394, a selective orally bioavailable small-molecule agonist, could remodel the tumor stroma and enhance responses to targeted and immune-based therapies.Methods TRND8394 was evaluated in RXFP1-humanized immunocompetent mouse models (hRXFP1) because the compound selectively activates human RXFP1 but not the murine receptor. Antitumor activity was assessed in spontaneous hRXFP1, MMTV-HER2/neu breast tumors and in hRXFP1 BALB/c syngeneic 4T1 triple-negative breast cancer models. Mice received daily oral TRND8394 (10 mg/kg) alone or in combination with trastuzumab in MMTV-HER2/neu transgenic mice or anti-PD-L1 treatment in the hRXFP1 BALB/c mice implanted with syngeneic 4T1 tumors. Tumor growth, proliferation, fibrosis-associated gene expression, and collagen deposition were evaluated. Wild-type BALB/c mice lacking humanized RXFP1 served as pharmacological specificity controls.Results TRND8394 significantly remodeled the tumor microenvironment by reducing profibrotic gene expression and decreasing collagen-rich stromal encapsulation surrounding tumors. In MMTV-HER2/neu mice, TRND8394 reduced cellular proliferation by enhancing the activity of HER2-targeted antibody therapy. In the 4T1 model, TRND8394 potentiated anti-PD-L1 therapy, resulting in reduced tumor burden and diminished invasion into adjacent muscle and abdominal tissues. Notably, implanted and spontaneous tumor cells did not express human RXFP1, indicating that antitumor activity resulted from modulation of the tumor stroma rather than direct effects on malignant cells. Consistent with an on-target mechanism, TRND8394 demonstrated no antitumor activity in wild-type BALB/c mice lacking humanized RXFP1.Conclusions Selective activation of RXFP1 remodels the fibrotic tumor microenvironment and enhances the efficacy of both targeted therapy and immune checkpoint blockade. These findings identify stromal RXFP1 signaling as a novel therapeutic axis to overcome tumor-promoting fibrosis and improve antitumor immune responses. TRND8394 represents a promising orally available stromal-targeted agent for combination immunotherapy strategies in solid tumors.Ethics Approval This work does not involve human subject research. Animal experimentation procedures have been approved following the OLAW Animal Welfare Assurance procedures for University of South Florida (protocol numbers: M IS00013292 and M IS00013336)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225138053
Cites:
Cited by:
Related to: 10